DE60016625D1 - Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g-proteinen in kombination mit einem anderen anti-krebs mittel zu einer therapeutischen verwendung in der krebsbehandlung - Google Patents

Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g-proteinen in kombination mit einem anderen anti-krebs mittel zu einer therapeutischen verwendung in der krebsbehandlung

Info

Publication number
DE60016625D1
DE60016625D1 DE2000616625 DE60016625T DE60016625D1 DE 60016625 D1 DE60016625 D1 DE 60016625D1 DE 2000616625 DE2000616625 DE 2000616625 DE 60016625 T DE60016625 T DE 60016625T DE 60016625 D1 DE60016625 D1 DE 60016625D1
Authority
DE
Germany
Prior art keywords
cancer
heterotrimeric
signal transduction
therapeutic use
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE2000616625
Other languages
English (en)
Other versions
DE60016625T2 (de
Inventor
Gregoire Prevost
Marie-Odile Lonchampt
Thomas Gordon
Barry Morgan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9914037A external-priority patent/FR2800616B1/fr
Priority claimed from FR0000104A external-priority patent/FR2803524B1/fr
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Publication of DE60016625D1 publication Critical patent/DE60016625D1/de
Application granted granted Critical
Publication of DE60016625T2 publication Critical patent/DE60016625T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60016625T 1999-11-09 2000-11-08 Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g-proteinen in kombination mit einem anderen anti-krebs-mittel zu einer therapeutischen verwendung in der krebsbehandlung Expired - Lifetime DE60016625T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9914037A FR2800616B1 (fr) 1999-11-09 1999-11-09 Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
FR9914037 1999-11-09
FR0000104A FR2803524B1 (fr) 2000-01-06 2000-01-06 Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
FR0000104 2000-01-06
PCT/FR2000/003098 WO2001034203A1 (fr) 1999-11-09 2000-11-08 Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer

Publications (2)

Publication Number Publication Date
DE60016625D1 true DE60016625D1 (de) 2005-01-13
DE60016625T2 DE60016625T2 (de) 2005-12-22

Family

ID=26212071

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60016625T Expired - Lifetime DE60016625T2 (de) 1999-11-09 2000-11-08 Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g-proteinen in kombination mit einem anderen anti-krebs-mittel zu einer therapeutischen verwendung in der krebsbehandlung

Country Status (15)

Country Link
US (3) US7034024B1 (de)
EP (2) EP1430934A1 (de)
JP (1) JP2003513940A (de)
AT (1) ATE284224T1 (de)
AU (1) AU1400401A (de)
CA (1) CA2390317C (de)
CZ (1) CZ20021550A3 (de)
DE (1) DE60016625T2 (de)
DK (1) DK1233787T3 (de)
ES (1) ES2234692T3 (de)
HU (1) HUP0203241A3 (de)
PL (1) PL204716B1 (de)
PT (1) PT1233787E (de)
RU (1) RU2298417C2 (de)
WO (1) WO2001034203A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2825278A1 (fr) * 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
FR2834289B1 (fr) 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
KR100594353B1 (ko) * 2002-05-28 2006-07-03 주식회사 엠디바이오알파 신규한 인삼잎 및 줄기 다당체, 그 제조방법 및 그를활성성분으로 함유하는 항암제 및 항암보조제 조성물
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2877667B1 (fr) 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879598B1 (fr) 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
CA2620223A1 (en) 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
AR077463A1 (es) 2009-07-09 2011-08-31 Irm Llc Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias
DE102009033392A1 (de) * 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
MX368615B (es) * 2012-09-25 2019-10-09 Hoffmann La Roche Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos.
MA39792B1 (fr) 2014-03-26 2019-12-31 Hoffmann La Roche Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa)
CN106317057B (zh) * 2015-07-02 2019-02-01 北京桦冠医药科技有限公司 具有咪唑并吡嗪类衍生物，其制备及其在医药上的应用
UA123362C2 (uk) 2015-09-04 2021-03-24 Ф. Хоффманн-Ля Рош Аг Феноксиметильні похідні
AU2018233079B9 (en) 2017-03-16 2021-07-22 F. Hoffmann-La Roche Ag Heterocyclic compounds useful as dual ATX/CA inhibitors
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
AU2018260414A1 (en) 2017-04-24 2019-10-17 Novartis Ag Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone and combinations thereof
CN112480122B (zh) * 2020-11-24 2022-03-22 中山大学 一种四氢咪唑[1,2-a]吡嗪类化合物、组合物及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH0517353A (ja) * 1991-07-10 1993-01-26 Kanebo Ltd 制癌作用増強剤
US5731334A (en) * 1994-01-11 1998-03-24 The Scripps Research Institute Method for treating cancer using taxoid onium salt prodrugs
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
EP0865440B1 (de) * 1995-12-08 2002-04-03 Janssen Pharmaceutica N.V. (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
US6673927B2 (en) * 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
WO1999007705A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
HUP0102473A3 (en) * 1997-12-22 2003-07-28 Schering Corp Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase

Also Published As

Publication number Publication date
CA2390317A1 (fr) 2001-05-17
EP1233787A1 (de) 2002-08-28
PT1233787E (pt) 2005-04-29
ES2234692T3 (es) 2005-07-01
JP2003513940A (ja) 2003-04-15
EP1430934A1 (de) 2004-06-23
AU1400401A (en) 2001-06-06
EP1233787B8 (de) 2005-05-18
HUP0203241A2 (hu) 2003-02-28
RU2298417C2 (ru) 2007-05-10
RU2002115262A (ru) 2004-01-27
DK1233787T3 (da) 2005-08-15
US7034024B1 (en) 2006-04-25
PL204716B1 (pl) 2010-02-26
ATE284224T1 (de) 2004-12-15
CA2390317C (fr) 2010-03-23
DE60016625T2 (de) 2005-12-22
PL356028A1 (en) 2004-06-14
EP1233787B1 (de) 2004-12-08
US20060074078A1 (en) 2006-04-06
HUP0203241A3 (en) 2006-07-28
US20090270341A1 (en) 2009-10-29
WO2001034203A1 (fr) 2001-05-17
CZ20021550A3 (cs) 2003-02-12

Similar Documents

Publication Publication Date Title
DE60016625D1 (de) Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g-proteinen in kombination mit einem anderen anti-krebs mittel zu einer therapeutischen verwendung in der krebsbehandlung
MX9705273A (es) Inhibidores de prenil transferasas.
NO903944L (no) Fremgangsmaate for fremstilling av nye peptidase og isomerase-inhibitorer.
HUP0202708A3 (en) Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
MD960330A (ro) Compuşi nepeptidilici, compoziţie farmaceutică pe baza acestora, metodă de tratament
CY1105286T1 (el) Ω-καρβοξυαρυλυποκατεστημενες διφαινυλουριες σαν αναστολεις της raf κινασης
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
SE9800836D0 (sv) New Compounds
ATE375794T1 (de) Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
HUP0301246A2 (hu) Humán véralvadási faktor VII változatai
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
BR0009914A (pt) Medicamento, e, usos de um inibidor, e de um ativador de quinase h-sgk humana regulada por volume celular
HUP0402506A2 (hu) FBPáz inhibitorok és inzulinérzékenység-fokozók kombinációja diabétesz kezelésére
BG102106A (en) Phermaceutical composition containing proteinase inhibitor and monoglyceride
FI20020545A (fi) Eristetty DNA-molekyyli, joka koodaa interleukiini-1 inhibiittoria, sitä sisältävä vektori ja isäntäsolu, menetelmä interleukiini-1-inhibiittoreiden valmistamiseksi sekä niiden käyttö farmaseuttistenkoostumusten valmistamisessa
ATE553782T1 (de) Pharmazeutische zusammensetzungen enthaltend src und / oder yes und deren verwendung
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
GB0328180D0 (en) Combination
DE60112719D1 (de) Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterometrischen g proteinen in kombination mit einem antihypertensiven mittel zu einer therapeutischen verwendung in der behandlung von arterieller hypertonie
WO2001000184A3 (de) Kombination von mtp-inhibitoren und lipidsenkern und ihre verwendung in arzneimitteln
GB9811221D0 (en) Bacterial-pheromones and uses therefor
WO2000024766A3 (en) New transcription factor of mhc class ii genes, substances capable of inhibiting this new transcription factor and medical uses of these substances
SE9502259L (sv) Oligonukleotider för att inhibera expression av isoprenylproteintransferas
HUP0203118A3 (en) Beta disubstituted metalloprotease inhibitors, pharmaceutical compositions containing them and their use
DE69941292D1 (de) Schlange, pseudonaja textilis textilis

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: IPSEN PHARMA S.A.S., BOULOGNE-BILLANCOURT, FR